Centrus Energy Corp.

Executive Summary

SELL, Medium conviction. Rated SELL, Medium conviction. LEU has improved its strategic position, with $4.5B backlog, a $900M DOE task order, and new HALEU offtake agreements, but the stock still trades at 57.92x FY2025 EPS and 6.1x sales while FY26 guidance was only reaffirmed and first meaningful new capacity is still targeted for 2029. The setup is better than the quant target alone implies, but not good enough to justify a premium this large against a business with negative $0.1B FCF, 10.72x debt/EBITDA, and visible pre-build margin pressure.

Investment Thesis

LEU is not a broken story. It is an expensive story. The company has clearly strengthened its strategic position in the nuclear fuel chain, and the Q2 call added real evidence: backlog rose to $4.5B through 2040, financial contingencies were removed on more than $3B of customer LEU/HALEU contracts, and Centrus signed a $900M DOE task order to support large-scale LEU/HALEU capacity expansion. It also completed HALEU demo-contract production two weeks ahead of schedule and nearly 2 metric tons of HALEU UF6 for DOE. Those are not promotional data points. They matter.

The problem is price versus timing. At $145.23, the stock still trades on 57.92x FY2025 EPS and 6.1x sales, despite FY2025 revenue of only $0.4B and a business that is entering a heavy investment phase. Management reaffirmed FY26 revenue guidance at $450M-$500M and capex at $350M-$500M. It did not raise company-wide financial guidance. It raised hiring, which is useful for confidence in the project pipeline, but hiring is not earnings. First centrifuge completion at Oak Ridge is expected in 2026, yet first new capacity is still targeted for 2029. That leaves a long period where investors are paying for future scarcity economics while current margins absorb pre-build costs.

The near-term P&L is already showing that pressure. Q2 EBITDA was $0.03B on $176.1M of revenue, a 16.3% margin, down 810 bps from Q1 and 1,240 bps from the prior-year quarter. Net income fell to $16.8M from $28.9M, driven by higher SG&A, stock comp, and advanced technology costs. Free cash flow was negative $0.1B in FY2025, and leverage screens poorly at 10.72x debt/EBITDA, even though call commentary around $1.9B unrestricted cash makes liquidity less alarming than the leverage ratio alone.

What the case depends on is straightforward. First, backlog must convert into profitable deliveries on a schedule that the market can see, not just a 2040 endpoint. Second, 2029 capacity timing has to hold or improve, because the stock still embeds scarcity value. Third, margin pressure from the build must prove temporary. If those three things happen, LEU can earn into a premium valuation. At today's price, too much of that upside is already spoken for.

Key Metrics

Financial Strength

The balance sheet is mixed. Liquidity looks far better than the leverage ratios suggest, helped by management's disclosure of $1.9B unrestricted cash and a 5.39 current ratio, which gives LEU room to fund near-term hiring, supplier commitments, and construction work. But this is not a self-funding model today. FY2025 FCF was -$0.1B, total debt is $1.2B, and 10.72x debt/EBITDA leaves little margin for delays or cost creep if commercial cash receipts slip. Margins improved at the FY2025 level, but Q2 showed the next phase clearly, pre-build costs are hitting earnings before the 2029 capacity benefit arrives.

Competitive Position

LEU's moat is regulatory, technical, and geopolitical. In HALEU, scarcity is real, qualification cycles are long, and Western customers want non-Russian supply, which gives Centrus unusual strategic value for a company of this size. The moat is stronger now than a few years ago because contract contingencies have been removed on more than $3B of customer LEU/HALEU contracts, supplier coverage is moving from ~75% to a targeted 100%, and the DOE relationship has deepened via the $900M task order. The weak point is that the moat is not yet fully monetized at scale. It will not be durable if execution slips materially before the 2029 capacity step-up.

Management & Guidance

Management's latest guidance reads credible but not especially generous. The company reaffirmed FY26 revenue of $450M-$500M and capex of $350M-$500M, while raising Piketon hiring to more than 175 net new employees and maintaining at least 100 net new hires at Oak Ridge. That says the build is progressing, but management stopped short of raising financial expectations despite a supportive demand backdrop. The earnings track record is mixed rather than clean, with major beats in 2025-02-06, 2025-05-07, 2025-08-05, and 2026-05-05, offset by notable misses in 2024-10-28 and 2026-02-10. That pattern supports moderate confidence in execution, not blind trust.

Bull Case

• Strategic demand is real: backlog rose to $4.5B through 2040, helped by about $600M of added commercial LEU/HALEU enrichment sales.
• Execution on supply chain improved materially, with management expecting 100% of critical supplier contracts finalized by year-end after reaching about 75% in Q2.
• Balance sheet liquidity is stronger than the headline leverage suggests, with $1.9B unrestricted cash cited on the Q2 call and a 5.39 current ratio.
• Commercial traction in HALEU is improving, with signed offtake deals with Oklo, X-energy, and Antares, and management said structures generally include prepayments.

Bear Case

• Current earnings do not justify the stock price: FY2025 EPS was $4.33, yet shares trade at 57.92x earnings, far above the 13.2x peer average.
• Cash generation is weak for this stage of build-out, with FCF of -$0.1B, total debt of $1.2B, and 10.72x debt/EBITDA before the biggest capacity ramp arrives.
• Margins are already feeling the build: Q2 EBITDA margin was 16.3%, down 810 bps sequentially and 1,240 bps versus prior-year Q2, while net income fell to $16.8M from $28.9M.
• The timeline is long and still not pulled forward, with the first centrifuge in 2026 but first new capacity only in 2029, while management gave no 2027 capex guidance.

Valuation & Price Target

Engine price target $83.63 (-42.4% vs current), Low confidence.

• P/E Multiple: $23.86 (13% weight)
• PEG (growth-adjusted): $81.32 (20% weight)
• P/S Multiple: $56 (20% weight)
• Quality-adjusted: $125.48 (20% weight)
• DCF: $129.06 (12% weight)

The rating aligns with the quant baseline SELL, but with more nuance than the raw $83.63 target suggests. The company is strategically improving, which is why the higher-end methods in the blend, Quality-adjusted $125.48 and DCF $129.06, are not absurd. Still, the stock at $145.23 sits above every valuation method in the blend, while FY2025 fundamentals show only $0.4B revenue, $4.33 EPS, -$0.1B FCF, and leverage of 10.72x debt/EBITDA. The low-signal sell-side consensus, 3 buy / 5 hold / 0 sell, likely reflects the strategic appeal of HALEU and DOE support, but that context does not offset the gap between present fundamentals and current valuation.

Risk Assessment

Risk score 59/100 (Moderate). The biggest risk to a SELL call is that LEU's HALEU scarcity value and government-backed buildout convert its $4.5B backlog into much higher earnings well before 2029, making today's 57.92x multiple look less extreme than current financials suggest.

The Bottom Line

LEU rates a SELL at Medium conviction. The company has real strategic assets and a better long-term position than many commodity-linked names, but the stock still asks investors to pay up today for capacity and earnings that are mostly a 2029 story. The market has already discounted a meaningful portion of the good news, even after the shares fell 68.7% from the high. A more positive view would require either a much lower entry price, or new evidence that backlog conversion, margin durability, and capacity timing can pull material earnings power forward. Until then, the story is better than the valuation.